A randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND # 117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
Contact phone
Neelam Singh, PhD | 517.364.5591
Principal investigator
Dr. Renuka Gera, MD
Trial Category
Childhood Cancers
Trial SubCategory
Lymphoma
Webform